[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Apomorphine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Apomorphine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Apomorphine.]
[J01EC02, sulfadiazine, The metabolism of Apomorphine can be decreased when combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Apomorphine.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Apomorphine is combined with Sulthiame.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Apomorphine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Apomorphine.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Apomorphine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Terbutaline.]
[G03BA03, testosterone, The metabolism of Apomorphine can be decreased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tetracaine.]
[N05AE05, lurasidone, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[L04AX02, thalidomide, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Apomorphine can be decreased when combined with Theophylline.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Eribulin.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Apomorphine.]
[L01AC01, thiotepa, The metabolism of Apomorphine can be decreased when combined with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Apomorphine.]
[N05AB08, thioproperazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Thioridazine.]
[N05AF04, thiothixene, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Thiothixene.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Apomorphine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Apomorphine.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tolazoline.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Apomorphine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Apomorphine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Apomorphine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Apomorphine.]
[S01BA05, triamcinolone, The metabolism of Apomorphine can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Apomorphine.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Triazolam.]
[C03AA06, trichlormethiazide, Apomorphine may increase the hypotensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Apomorphine can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Apomorphine.]
[C02BA01, trimethaphan, Apomorphine may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Apomorphine can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Apomorphine.]
[A03BB01, butylscopolamine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Apomorphine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Apomorphine.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Apomorphine is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tubocurarine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Apomorphine can be decreased when combined with Abiraterone.]
[J05AP03, boceprevir, The metabolism of Apomorphine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Telaprevir can be decreased when combined with Apomorphine.]
[J05AG05, rilpivirine, The metabolism of Apomorphine can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ezogabine.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Apomorphine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Apomorphine.]
[C08DA01, verapamil, The metabolism of Apomorphine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Viloxazine.]
[C04AX07, vincamine, Apomorphine may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Apomorphine.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Warfarin.]
[C03BA10, xipamide, Apomorphine may increase the hypotensive activities of Xipamide.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Pipemidic acid.]
[J05AF01, zidovudine, The metabolism of Apomorphine can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Apomorphine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Levetiracetam.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Vemurafenib.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Apomorphine.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Apomorphine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ziprasidone.]
[G04BD07, tolterodine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Apomorphine.]
[J02AC03, voriconazole, The metabolism of Apomorphine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Apomorphine is combined with Atracurium.]
[S01FA01, atropine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Apomorphine.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Apomorphine.]
[H02AB11, prednylidene, The metabolism of Apomorphine can be increased when combined with Prednylidene.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Apomorphine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Apomorphine can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, The metabolism of Apomorphine can be decreased when combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Apomorphine can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The metabolism of Apomorphine can be decreased when combined with Teriflunomide.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Apomorphine.]
[J05AE04, nelfinavir, The metabolism of Apomorphine can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Apomorphine.]
[C08CA13, lercanidipine, The risk or severity of adverse effects can be increased when Lercanidipine is combined with Apomorphine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Apomorphine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Apomorphine is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Apomorphine.]
[R06AC06, thonzylamine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Apomorphine is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Apomorphine can be decreased when combined with Cabozantinib.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Apomorphine can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Apomorphine.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Apomorphine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Apomorphine.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Apomorphine.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Benperidol.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Moxifloxacin.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Apomorphine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Apomorphine is combined with Naratriptan.]
[N04AC01, benztropine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Apomorphine can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Apomorphine can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Apomorphine is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Apomorphine.]
[C02KX04, macitentan, Apomorphine may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Apomorphine.]
[N06AX26, vortioxetine, The risk or severity of hypotension can be increased when Vortioxetine is combined with Apomorphine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dapagliflozin.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Apomorphine can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Apomorphine can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Apomorphine.]
[C02CC01, bethanidine, Apomorphine may increase the hypotensive activities of Bethanidine.]
[C10AB02, bezafibrate, The metabolism of Apomorphine can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Apomorphine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ceritinib.]
[A03BA03, hyoscyamine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Alfaxalone.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Olodaterol.]
[D11AA01, glycopyrronium, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Eliglustat.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Acepromazine.]
[N04AA02, biperiden, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Apomorphine.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Apomorphine.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dicoumarol.]
[N06AX11, mirtazapine, Apomorphine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Apomorphine can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Apomorphine.]
[A03AA09, difemerine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Apomorphine.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Flibanserin.]
[N05AX15, cariprazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Apomorphine can be decreased when combined with Lansoprazole.]
[J02AC05, isavuconazole, The metabolism of Apomorphine can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Apomorphine.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Apomorphine.]
[A03FA05, alizapride, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Alizapride.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Apomorphine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Apomorphine is combined with Aprobarbital.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apomorphine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Amineptine.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Amlodipine is combined with Apomorphine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Aniracetam.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Apomorphine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Bupranolol.]
[N07BC01, buprenorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Apomorphine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Artemether.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Apomorphine.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Azatadine.]
[S01GX07, azelastine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Apomorphine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Apomorphine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Beclamide.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Apomorphine.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Apomorphine.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Apomorphine.]
[L04AB02, infliximab, The metabolism of Apomorphine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Apomorphine can be increased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Apomorphine.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Apomorphine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Delafloxacin.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Apomorphine.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Apomorphine.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Apomorphine.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Apomorphine.]
[N04AA11, bornaprine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nesiritide.]
[A03FA04, bromopride, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Bromopride.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Brotizolam.]
[R03BA02, budesonide, The metabolism of Apomorphine can be increased when combined with Budesonide.]
[L01EL02, acalabrutinib, The metabolism of Apomorphine can be decreased when combined with Acalabrutinib.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Apomorphine is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Apomorphine can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Apomorphine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Acetyldigoxin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Apomorphine is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Acrivastine.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Apomorphine is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be decreased when combined with Apomorphine.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Apomorphine.]
[A03AA03, camylofine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Carbinoxamine.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Apomorphine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Apomorphine.]
[B02BX08, avatrombopag, The metabolism of Apomorphine can be increased when combined with Avatrombopag.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Encorafenib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Apomorphine.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Apomorphine can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Apomorphine can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Apomorphine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Apomorphine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Apomorphine is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Inotersen.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Apomorphine.]
[R03BB08, revefenacin, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Apomorphine.]
[L04AA39, emapalumab, The metabolism of Apomorphine can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Apomorphine is combined with Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Apomorphine is combined with Cinitapride.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Apomorphine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Brexanolone.]
[A03FA06, clebopride, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Clebopride.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Apomorphine.]
[H02AB14, cloprednol, The metabolism of Apomorphine can be increased when combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Cloxazolam.]
[C09CA06, candesartan, The metabolism of Apomorphine can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Apomorphine can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Apomorphine can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Apomorphine can be decreased when combined with Alpelisib.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Cyamemazine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Apomorphine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Entrectinib.]
[N07XX11, pitolisant, Apomorphine may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Apomorphine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Apomorphine.]
[C03AA09, cyclothiazide, Apomorphine may increase the hypotensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Yohimbine.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Apomorphine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Apomorphine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Apomorphine.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Apomorphine.]
[N03AX25, cenobamate, The serum concentration of Apomorphine can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apomorphine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dezocine.]
[N05CM21, lemborexant, The serum concentration of Apomorphine can be decreased when it is combined with Lemborexant.]
[N05AD10, lumateperone, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lumateperone.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Osilodrostat can be decreased when combined with Apomorphine.]
[J05AE05, amprenavir, The metabolism of Apomorphine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Apomorphine is combined with Frovatriptan.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Apomorphine.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Apomorphine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Apomorphine.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Apomorphine.]
[M01AH02, rofecoxib, The metabolism of Apomorphine can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Apomorphine can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be decreased when combined with Apomorphine.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Valpromide.]
[S03AA08, chloramphenicol, The metabolism of Apomorphine can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Apomorphine.]
[C02AA06, methoserpidine, Apomorphine may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Apomorphine.]
[A03AA08, dihexyverine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The metabolism of Apomorphine can be decreased when combined with Opicapone.]
[C01CA14, dopexamine, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Dopexamine.]
[D07XB03, fluprednidene, The metabolism of Apomorphine can be increased when combined with Fluprednidene.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Apomorphine.]
[G04BD09, trospium, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[L01EX22, selpercatinib, The serum concentration of Apomorphine can be increased when it is combined with Selpercatinib.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Apomorphine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Apomorphine.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be decreased when combined with Apomorphine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Fostemsavir.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Remimazolam.]
[N07XX04, sodium oxybate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Apomorphine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Apomorphine can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Apomorphine can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Chlorpromazine.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Apomorphine.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Apomorphine.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ethyl loflazepate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Apomorphine can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Relugolix.]
[P03AX07, abametapir, The serum concentration of Apomorphine can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Apomorphine is combined with Vericiguat.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Felbamate.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Fenoldopam.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Apomorphine.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Flumequine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Apomorphine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Apomorphine is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Apomorphine may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Apomorphine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Gabapentin.]
[N07CA02, cinnarizine, The metabolism of Apomorphine can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The metabolism of Apomorphine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The metabolism of Apomorphine can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Apomorphine is combined with Citalopram.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Apomorphine.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Apomorphine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Clemastine.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Apomorphine.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Apomorphine is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Apomorphine.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Clofazimine.]
[B06AX04, mitapivat, The metabolism of Apomorphine can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Apomorphine.]
[C01EB24, mavacamten, The metabolism of Apomorphine can be increased when combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Apomorphine.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Clothiapine.]
[H01CC04, linzagolix, The serum concentration of Apomorphine can be increased when it is combined with Linzagolix.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Apomorphine.]
[A04AA02, granisetron, The risk or severity of hypotension can be increased when Granisetron is combined with Apomorphine.]
[N05AH02, clozapine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Halazepam.]
[S02DA02, cocaine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Apomorphine may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Apomorphine can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Apomorphine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Apomorphine is combined with Hexafluronium.]
[A03AB10, hexocyclium, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Apomorphine is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of hypotension can be increased when Tropisetron is combined with Apomorphine.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Apomorphine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Desloratadine.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Apomorphine is combined with Almotriptan.]
[J02AC02, itraconazole, The metabolism of Apomorphine can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Emedastine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ketazolam.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Posaconazole.]
[C08CA09, lacidipine, Apomorphine may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Levocabastine.]
[S01BA03, cortisone, The metabolism of Apomorphine can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Apomorphine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Lomefloxacin.]
[R06AX13, loratadine, The metabolism of Apomorphine can be decreased when combined with Loratadine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Lormetazepam.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Apomorphine is combined with Lisinopril.]
[C08CA11, manidipine, The metabolism of Apomorphine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Medifoxamine.]
[H02AB15, meprednisone, The metabolism of Apomorphine can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Adenosine.]
[N04AA03, methixene, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Apomorphine is combined with Cyclobarbital.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Apomorphine.]
[N05AD03, metylperon, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Melperone.]
[C03AA07, cyclopenthiazide, Apomorphine may increase the hypotensive activities of Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Apomorphine.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Apomorphine.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Apomorphine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Apomorphine.]
[N06BA07, modafinil, The metabolism of Apomorphine can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Apomorphine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Apomorphine.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Apomorphine is combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Vardenafil.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Apomorphine can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Apomorphine can be increased when combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Deanol.]
[C02CC04, debrisoquin, Apomorphine may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nordazepam.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nebivolol.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Apomorphine.]
[L02BB02, nilutamide, The metabolism of Apomorphine can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tiagabine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Apomorphine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Escitalopram.]
[G04BD08, solifenacin, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Apomorphine is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Oxaliplatin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Apomorphine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxiracetam.]
[N04AA08, dexetimide, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Apomorphine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Apomorphine can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Apomorphine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Apomorphine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Apomorphine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Apomorphine can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenacemide.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Apomorphine.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Apomorphine can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Apomorphine.]
[A03AA07, dicyclomine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Apomorphine may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Pinaverium.]
[A10BG03, pioglitazone, The metabolism of Apomorphine can be decreased when combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Pipamperone.]
[A03AB14, pipenzolate, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Apomorphine.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Apomorphine is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Apomorphine can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Apomorphine.]
[D07XC04, diflucortolone, The metabolism of Apomorphine can be increased when combined with Difluocortolone.]
[A03AB11, poldine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Apomorphine.]
[C02DB01, dihydralazine, Apomorphine may increase the hypotensive activities of Dihydralazine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Apomorphine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Apomorphine.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Apomorphine.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Apomorphine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Pridinol.]
[R06AB03, dimethindene, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Progabide.]
[R06AA02, diphenhydramine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Quazepam.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Apomorphine is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Apomorphine.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Apomorphine.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Apomorphine.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Apomorphine.]
[C01BA03, disopyramide, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Apomorphine can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Apomorphine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Apomorphine is combined with Riluzole.]
[N05AX08, risperidone, Apomorphine may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Apomorphine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Rosoxacin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Apomorphine.]
[A04AD12, aprepitant, The metabolism of Apomorphine can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Apomorphine.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be decreased when combined with Apomorphine.]
[S01BC05, ketorolac, The metabolism of Apomorphine can be decreased when combined with Ketorolac.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Apomorphine.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Apomorphine can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Apomorphine.]
[N06AA12, doxepin, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Apomorphine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Apomorphine is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Apomorphine can be decreased when combined with Simvastatin.]
[C09AA11, spirapril, Apomorphine may increase the hypotensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Apomorphine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Apomorphine.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Temafloxacin.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Terazosin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Apomorphine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Terodiline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Apomorphine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Thiopropazate.]
[G04BD01, emepronium, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Enalapril is combined with Apomorphine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Tofisopam.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Apomorphine.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Apomorphine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Apomorphine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Toremifene.]
[C03CA04, torsemide, The metabolism of Apomorphine can be decreased when combined with Torasemide.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Apomorphine.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Apomorphine is combined with Triclofos.]
[A03AB08, tridihexethyl, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Apomorphine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Triptorelin.]
[N04AA12, tropatepine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Apomorphine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Apomorphine is combined with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Apomorphine.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Apomorphine is combined with Veralipride.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Venlafaxine.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Barnidipine.]
[C09AA15, zofenopril, Apomorphine may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Zopiclone.]
[N05AX11, zotepine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Guanfacine.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Apomorphine is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Apomorphine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Apomorphine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Valproic acid.]
[S01AA17, erythromycin, The metabolism of Apomorphine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Estazolam.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Apomorphine.]
[R03BA09, fluticasone furoate, The metabolism of Apomorphine can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Apomorphine can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Apomorphine can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Apomorphine.]
[L02AA03, ethinyl estradiol, The metabolism of Apomorphine can be decreased when combined with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Amifostine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ibutilide.]
[N04AA05, profenamine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Apomorphine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ethotoin.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Apomorphine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Apomorphine.]
[N05AE03, sertindole, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ajmaline.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Apomorphine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Apomorphine.]
[R06AX12, terfenadine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Apomorphine.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Famotidine.]
[C08CA02, felodipine, The metabolism of Apomorphine can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Fenfluramine.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Apomorphine is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Salbutamol.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Apomorphine.]
[G04BD02, flavoxate, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Flecainide.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Apomorphine.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The metabolism of Apomorphine can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Apomorphine is combined with Melitracen.]
[H02AB03, fluocortolone, The metabolism of Apomorphine can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Apomorphine.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Fluoxetine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Flupentixol.]
[N05AB02, fluphenazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Apomorphine.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Apomorphine is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Apomorphine can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Apomorphine.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Apomorphine is combined with Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Apomorphine.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Furosemide is combined with Apomorphine.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Apomorphine is combined with Eszopiclone.]
[N05AL05, amisulpride, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Apomorphine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Gallopamil.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Apomorphine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Apomorphine is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Apomorphine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Degarelix.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Apomorphine.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be decreased when Cabergoline is combined with Apomorphine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Apomorphine is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Apomorphine.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Apomorphine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Glutethimide.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Dofetilide.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Apomorphine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Apomorphine.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Apomorphine.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Apomorphine is combined with Fluindione.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Fosinopril is combined with Apomorphine.]
[S01EX01, guanethidine, Apomorphine may increase the hypotensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Apomorphine is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Apomorphine is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Apomorphine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Apomorphine is combined with Allobarbital.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Apomorphine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Apomorphine.]
[J05AG01, nevirapine, The metabolism of Apomorphine can be increased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Apomorphine can be decreased when combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Apomorphine is combined with Perindopril.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Apomorphine can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Hydroflumethiazide.]
[G04BD06, propiverine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Apomorphine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Apomorphine can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Apomorphine may increase the hypotensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Apomorphine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Apomorphine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Apomorphine.]
[N06AA02, imipramine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Apomorphine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Apomorphine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Indapamide.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Apomorphine is combined with Milnacipran.]
[A03AA30, piperidolate, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Articaine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Apomorphine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Apomorphine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ramelteon.]
[R06AE01, buclizine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Apomorphine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Alprenolol.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Apomorphine is combined with Iprindole.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Apomorphine.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Apomorphine.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Apomorphine is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Apomorphine is combined with Isoflurane.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Apomorphine.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Isoniazid.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Isosorbide dinitrate.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Isoxsuprine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Apomorphine.]
[L04AC07, tocilizumab, The metabolism of Apomorphine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Apomorphine.]
[J02AB02, ketoconazole, The metabolism of Apomorphine can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Apomorphine can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The metabolism of Apomorphine can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Apomorphine can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Apomorphine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Mizolastine.]
[N04BC09, rotigotine, Apomorphine may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Nalidixic acid.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Apomorphine.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Amantadine.]
[C02AA05, deserpidine, Apomorphine may increase the hypotensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Apomorphine is combined with Etacrynic acid.]
[G03AD01, levonorgestrel, The metabolism of Apomorphine can be decreased when combined with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Apomorphine is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Apomorphine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Apomorphine can be increased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Apomorphine.]
[N02CA07, lisuride, The risk or severity of adverse effects can be decreased when Lisuride is combined with Apomorphine.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Lofepramine.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Apomorphine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Apomorphine.]
[C10AA02, lovastatin, The metabolism of Apomorphine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Loxapine.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Apomorphine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Apomorphine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Mannitol.]
[N06AA21, maprotiline, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Apomorphine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Apomorphine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Meclizine.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Medazepam.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Apomorphine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Melatonin.]
[N06DX01, memantine, The metabolism of Apomorphine can be decreased when combined with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Apomorphine.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Apomorphine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Apomorphine.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Apomorphine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Meptazinol.]
[N05AC03, mesoridazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Mesoridazine.]
[N05AX13, paliperidone, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of hypotension can be increased when Dolasetron is combined with Apomorphine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Apomorphine.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Metamfetamine.]
[A03AB07, methantheline, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Apomorphine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Apomorphine.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Apomorphine.]
[G02CB05, metergoline, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Apomorphine can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Apomorphine.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Apomorphine.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Apomorphine is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Apomorphine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Apomorphine is combined with Methyldopa.]
[V04CG05, methylene blue, Apomorphine may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Methylergometrine.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Apomorphine.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Apomorphine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Apomorphine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Apomorphine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Apomorphine.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Metolazone is combined with Apomorphine.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Apomorphine.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Metronidazole.]
[C01BB02, mexiletine, The metabolism of Apomorphine can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Apomorphine is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Apomorphine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Apomorphine.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Apomorphine.]
[G03XB01, mifepristone, The serum concentration of Apomorphine can be increased when it is combined with Mifepristone.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Apomorphine.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Apomorphine.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Lisdexamfetamine.]
[N05AE02, molindone, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Molindone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apomorphine.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Apomorphine.]
[N06AA09, amitriptyline, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Apomorphine.]
[A04AA05, palonosetron, The risk or severity of hypotension can be increased when Palonosetron is combined with Apomorphine.]
[L04AB05, certolizumab pegol, The metabolism of Apomorphine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Apomorphine can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Apomorphine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Apomorphine is combined with Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Apomorphine.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Apomorphine.]
[R03BB01, ipratropium bromide, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G03XC01, raloxifene, The metabolism of Apomorphine can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Apomorphine.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nadolol.]
[N04BC04, ropinirole, Apomorphine may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Apomorphine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Apomorphine.]
[L04AC03, anakinra, The metabolism of Apomorphine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Apomorphine.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Apomorphine.]
[A10BG01, troglitazone, The metabolism of Apomorphine can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Apomorphine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Apomorphine.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Apomorphine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Apomorphine is combined with Remifentanil.]
[A10BX02, repaglinide, The metabolism of Repaglinide can be decreased when combined with Apomorphine.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Levosimendan.]
[N05AX14, iloperidone, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Apomorphine.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Apomorphine is combined with Telmisartan.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Apomorphine.]
[C08CA04, nicardipine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N07BA01, nicotine, The metabolism of Apomorphine can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Nifedipine.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Apomorphine is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of adverse effects can be increased when Nisoldipine is combined with Apomorphine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Apomorphine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Apomorphine is combined with Zaleplon.]
[N04BC05, pramipexole, Apomorphine may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Nitroprusside is combined with Apomorphine.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nomifensine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Apomorphine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Norfloxacin.]
[C02KX01, bosentan, Apomorphine may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Apomorphine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Apomorphine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Apomorphine can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Apomorphine is combined with Opium.]
[G02CB04, quinagolide, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Quinagolide.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Tamsulosin is combined with Apomorphine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Apomorphine.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxypertine.]
[A03AB03, oxyphenonium, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Apomorphine.]
[N05AH05, asenapine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[M03AC01, pancuronium, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Papaverine.]
[N05CC05, paraldehyde, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Apomorphine can be increased when combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Apomorphine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Apomorphine.]
[G04BD11, fesoterodine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Apomorphine.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Apomorphine.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Perhexiline.]
[N05AB03, perphenazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Apomorphine.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Apomorphine can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Apomorphine.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Apomorphine.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Phentolamine is combined with Apomorphine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Apomorphine.]
[L04AB06, golimumab, The metabolism of Apomorphine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Levofloxacin.]
[C08CX01, mibefradil, The metabolism of Apomorphine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Apomorphine.]
[J05AE01, saquinavir, The metabolism of Apomorphine can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Pipotiazine.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Apomorphine is combined with Eprosartan.]
[A02BX03, pirenzepine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Piribedil.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Apomorphine is combined with Piritramide.]
[S01BC06, piroxicam, The metabolism of Apomorphine can be decreased when combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Grepafloxacin.]
[N02CX01, pizotyline, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Apomorphine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Apomorphine can be decreased when combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Apomorphine is combined with Proxibarbal.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Apomorphine.]
[A10BG02, rosiglitazone, The metabolism of Apomorphine can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Apomorphine.]
[A03AE01, alosetron, The risk or severity of hypotension can be increased when Alosetron is combined with Apomorphine.]
[L04AC08, canakinumab, The metabolism of Apomorphine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Apomorphine may increase the hypotensive activities of Polythiazide.]
[J05AE03, ritonavir, The metabolism of Apomorphine can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Apomorphine.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Apomorphine.]
[C07AB01, practolol, Apomorphine may increase the hypotensive activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Prajmaline.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Apomorphine is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Apomorphine.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Apomorphine.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Primaquine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Apomorphine.]
[M04AB01, probenecid, The metabolism of Apomorphine can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Procainamide.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Apomorphine.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Apomorphine.]
[C10AB05, fenofibrate, The metabolism of Apomorphine can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Prochlorperazine.]
[N04AA04, procyclidine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Apomorphine can be decreased when combined with Progesterone.]
[N05AA03, promazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Apomorphine is combined with Propanidid.]
[A03AB05, propantheline, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Apomorphine.]
[C07AA05, propranolol, The risk or severity of adverse effects can be increased when Propranolol is combined with Apomorphine.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Apomorphine is combined with Rizatriptan.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Apomorphine is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Apomorphine can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Apomorphine.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Aripiprazole.]
[A03AB15, diphemanil, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Apomorphine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Apomorphine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Apomorphine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Apomorphine is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Mepyramine.]
[P01BD01, pyrimethamine, The metabolism of Apomorphine can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Apomorphine.]
[C01BA01, quinidine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Quinine.]
[C02AA01, rescinnamine, Apomorphine may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Apomorphine.]
[J04AB02, rifampin, The metabolism of Apomorphine can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Apomorphine is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Roxithromycin.]
[S01FA02, scopolamine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The metabolism of Apomorphine can be increased when combined with Secobarbital.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Apomorphine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Apomorphine is combined with Obinutuzumab.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Apomorphine.]
[C03DA01, spironolactone, The metabolism of Apomorphine can be decreased when combined with Spironolactone.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Apomorphine.]
